Evidence map›Paper›PMID 42234701›Full record

ReviewHuman vaccines & immunotherapeutics2026

Depemokimab: A twice yearly anti-IL 5 biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) - A narrative review.

Marn Joon Park, Joseph K Han, Kent K Lam

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marn Joon ParkDepartment of Otolaryngology - Head & Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Joseph K HanDepartment of Otolaryngology - Head & Neck Surgery, Macon & Joan Brock Virginia Health Sciences, Eastern Virginia Medical School of Old Dominion University, Norfolk, NE, USA.
Kent K LamDepartment of Otolaryngology - Head & Neck Surgery, Macon & Joan Brock Virginia Health Sciences, Eastern Virginia Medical School of Old Dominion University, Norfolk, NE, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depemokimab is a monoclonal antibody that targets interleukin-5 with enhanced binding affinity and an extended terminal elimination half‑life of 6-8 weeks. The unique pharmacodynamic features of depemokimab enable sustained suppression of type 2 inflammation with twice‑yearly subcutaneous dosing. This narrative review provides details of depemokimab's molecular profile, pharmacokinetics, and pharmacodynamics and results regarding the clinical efficacy and safety of depemokimab from recently published Phase 3 clinical trials for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). In 528 severe adult CRSwNP patients (ANCHOR‑1/‑2 trials), depemokimab achieved Δ total endoscopic nasal polyp score by -0.70 (

Indexed as

Antibodies, Monoclonal, HumanizedInterleukin-5Nasal PolypsRhinosinusitisChronic DiseaseClinical Trials, Phase III as TopicEosinophilsHumansTreatment OutcomeAntibodies, Monoclonal, HumanizedInterleukin-5mepolizumabbiologicschronic rhinosinusitis with nasal polyposisCRSwNPDepemokimabeosinophilIL-5interleukin‑5mepolizumabtype 2 inflammation

Identifiers

PMID42234701
PMCPMC13240964

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.